Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/HECTD1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/HECTD1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/HECTD1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/HECTD1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/HECTD1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/HECTD1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/HECTD1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/HECTD1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/HECTD1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00300985 | Skin | AK | lymphocyte differentiation | 57/1910 | 374/18723 | 1.34e-03 | 1.00e-02 | 57 |
GO:002191510 | Skin | AK | neural tube development | 28/1910 | 152/18723 | 1.44e-03 | 1.06e-02 | 28 |
GO:00032815 | Skin | AK | ventricular septum development | 16/1910 | 71/18723 | 1.80e-03 | 1.24e-02 | 16 |
GO:001402010 | Skin | AK | primary neural tube formation | 19/1910 | 94/18723 | 2.72e-03 | 1.74e-02 | 19 |
GO:00032054 | Skin | AK | cardiac chamber development | 28/1910 | 161/18723 | 3.44e-03 | 2.09e-02 | 28 |
GO:00705346 | Skin | AK | protein K63-linked ubiquitination | 13/1910 | 56/18723 | 3.55e-03 | 2.15e-02 | 13 |
GO:00031704 | Skin | AK | heart valve development | 14/1910 | 65/18723 | 5.22e-03 | 2.91e-02 | 14 |
GO:00018439 | Skin | AK | neural tube closure | 17/1910 | 88/18723 | 7.11e-03 | 3.64e-02 | 17 |
GO:00606068 | Skin | AK | tube closure | 17/1910 | 89/18723 | 7.98e-03 | 4.03e-02 | 17 |
GO:00607066 | Skin | AK | cell differentiation involved in embryonic placenta development | 7/1910 | 25/18723 | 1.05e-02 | 4.96e-02 | 7 |
GO:001049828 | Skin | cSCC | proteasomal protein catabolic process | 243/4864 | 490/18723 | 7.85e-30 | 4.10e-27 | 243 |
GO:004217629 | Skin | cSCC | regulation of protein catabolic process | 198/4864 | 391/18723 | 6.03e-26 | 1.89e-23 | 198 |
GO:004316128 | Skin | cSCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 205/4864 | 412/18723 | 1.46e-25 | 4.16e-23 | 205 |
GO:190336229 | Skin | cSCC | regulation of cellular protein catabolic process | 139/4864 | 255/18723 | 2.06e-22 | 4.17e-20 | 139 |
GO:190305029 | Skin | cSCC | regulation of proteolysis involved in cellular protein catabolic process | 121/4864 | 221/18723 | 6.75e-20 | 1.01e-17 | 121 |
GO:006113629 | Skin | cSCC | regulation of proteasomal protein catabolic process | 106/4864 | 187/18723 | 4.31e-19 | 5.87e-17 | 106 |
GO:003243429 | Skin | cSCC | regulation of proteasomal ubiquitin-dependent protein catabolic process | 80/4864 | 134/18723 | 1.54e-16 | 1.49e-14 | 80 |
GO:200005829 | Skin | cSCC | regulation of ubiquitin-dependent protein catabolic process | 92/4864 | 164/18723 | 2.30e-16 | 2.12e-14 | 92 |
GO:004586229 | Skin | cSCC | positive regulation of proteolysis | 169/4864 | 372/18723 | 2.43e-16 | 2.21e-14 | 169 |
GO:000989628 | Skin | cSCC | positive regulation of catabolic process | 206/4864 | 492/18723 | 6.06e-15 | 4.64e-13 | 206 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HECTD1 | SNV | Missense_Mutation | | c.6715N>A | p.Glu2239Lys | p.E2239K | Q9ULT8 | protein_coding | tolerated(0.11) | probably_damaging(0.973) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
HECTD1 | SNV | Missense_Mutation | | c.140N>G | p.Thr47Arg | p.T47R | Q9ULT8 | protein_coding | deleterious(0.01) | benign(0.148) | TCGA-A2-A0YM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HECTD1 | SNV | Missense_Mutation | | c.2228N>G | p.Pro743Arg | p.P743R | Q9ULT8 | protein_coding | deleterious(0) | possibly_damaging(0.896) | TCGA-A8-A08P-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
HECTD1 | SNV | Missense_Mutation | | c.5992G>C | p.Glu1998Gln | p.E1998Q | Q9ULT8 | protein_coding | deleterious(0.01) | benign(0.115) | TCGA-A8-A095-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
HECTD1 | SNV | Missense_Mutation | rs755152978 | c.3005N>A | p.Arg1002Gln | p.R1002Q | Q9ULT8 | protein_coding | deleterious(0) | probably_damaging(0.916) | TCGA-A8-A09W-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
HECTD1 | SNV | Missense_Mutation | rs748524391 | c.4411N>T | p.Arg1471Cys | p.R1471C | Q9ULT8 | protein_coding | deleterious(0.02) | benign(0.336) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HECTD1 | SNV | Missense_Mutation | | c.1259N>T | p.Ala420Val | p.A420V | Q9ULT8 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD |
HECTD1 | SNV | Missense_Mutation | | c.1510G>A | p.Glu504Lys | p.E504K | Q9ULT8 | protein_coding | tolerated(0.26) | benign(0.009) | TCGA-AR-A0TP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
HECTD1 | SNV | Missense_Mutation | | c.4696C>G | p.Leu1566Val | p.L1566V | Q9ULT8 | protein_coding | tolerated(0.29) | probably_damaging(0.931) | TCGA-B6-A0RG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HECTD1 | SNV | Missense_Mutation | novel | c.3858N>T | p.Trp1286Cys | p.W1286C | Q9ULT8 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |